Clin2
NCT07158814Possibly a fitRecruiting

Testing the safety of an RSV antibody in infants

FeverAdverse Event Following Immunisation

This study checks if it is safe to delay the RSV preventive antibody shot by up to two weeks in infants who are getting their routine vaccines. Your baby will get the antibody at a second visit.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 4
Enrollment
524 people
Ages
1 month to 7 months
Study type
Interventional

Who can take part

  • Your baby must be between 6 weeks and 30 weeks old
  • Your baby is already scheduled to receive an RSV antibody shot
  • Your baby is getting at least one routine childhood vaccine
  • You must be able to read and understand English or Spanish
  • You must be able to bring your baby to two visits and be reachable by phone

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07824167Not yet recruiting· Phase 4
RSV antibody study for babies under 8 months

This study tests a new antibody shot (called enflonsia) to help protect babies under 8 months old from RSV, a common virus that can cause breathing problems. If your baby qualifies, they will receive the shot and be followed for about 6 months to see how well it works.

Atlanta, Georgia
NCT07578298Recruiting· Phase 4
RSV protection for aboriginal infants

This study tests an RSV antibody shot that helps protect babies from severe RSV. It aims to see how well this preventive shot works in Aboriginal and Torres Strait Islander infants when given around 6-9 months of age.

Darwin, Northern Territory
NCT07041190Not yet recruiting· Phase 3
Protecting babies from RSV during pregnancy and after birth

This study tests two approved ways to prevent RSV, a common virus that can make babies very sick. Pregnant women may get a vaccine, and/or their babies may get an antibody shot after birth. The study compares these options to see which works best.

NCT07363837Not yet recruiting· Phase 1/Phase 2
RSV prevention injection for infants under one year

This study tests a new injection (SIBP-A16) designed to protect infants against RSV, a common virus that can cause serious lung infections in babies. The trial will see if the injection is safe and works in both premature and full-term infants during their first RSV season.

Chengdu, Sichuan
NCT07768345Recruiting· Phase 3
Revaccination with RSV vaccine for immunocompromised adults

This trial studies whether giving a booster dose of the RSV vaccine (Abrysvo) is safe and effective for adults with weakened immune systems. It includes people who have never had an RSV vaccine and those who had one or two doses in the past.

Los Angeles, California
NCT06172660Recruiting
RSV prevention study for babies in Connecticut

This study looks at how well RSV vaccines or antibody shots protect babies from severe respiratory infections. If your baby is under 1 year old, lives in Connecticut, and gets sick with a respiratory infection, they may be able to join.

New Haven, Connecticut

Hear when a new Fever trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.